Combining 53BP1 with BRCA1 as a biomarker to predict the sensitivity of poly(ADP-ribose) polymerase (PARP) inhibitors

Over half of patients with BRCA1-deficient cancers do not respond to treatment with poly(ADP-ribose) polymerase (PARP) inhibitors. In this study, we report that a combination of 53BP1 and BRCA1 may serve as a biomarker of PARP inhibitor sensitivity. Based on the mRNA levels of four homologous recomb...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Acta Pharmacol Sin
Main Authors: Yang, Zhong-min, Liao, Xue-mei, Chen, Yi, Shen, Yan-yan, Yang, Xin-ying, Su, Yi, Sun, Yi-ming, Gao, Ying-lei, Ding, Jian, Zhang, Ao, He, Jin-xue, Miao, Ze-hong
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2017
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5519258/
https://ncbi.nlm.nih.gov/pubmed/28414200
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/aps.2017.8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados